Q2 FY2026 EarningsQ2 FY26 results for GLSI were mixed compared to consensus, with a narrower GAAP net loss of -$3.95M vs. the -$4.99M expected, resulting in a beat on EPS (-$0.27 vs. -$0.33 expected). However, the operating cash burn was significantly higher than anticipated, with a 6-month outflow of -$6.64M compared to a full-period mean consensus of -$6.75M, suggesting an accelerated burn rate. The company remains pre-revenue as the Phase III Flamingo-01 trial continues to expand into Europe.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Greenwich Lifesciences(GLSI) the EBIT is -4.022 M (+0.6%), Beat estimate;the EPS is -0.27 (+10%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B0.60%
-0.01B23.58%
+0.00B24.18%
EPSExceed expectations
-0.2710.00%
-0.3310.00%
+0.060020.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf